Quantum signs agreement with CDMO to manufacture oral Lucid-21-302

Quantum BioPharma’s Huge Biopharma Australia has signed an agreement with a contract development and manufacturing organization to manufacture an oral drug formulation of Lucid-MS. The oral formulation of Lucid-MS will serve as the drug product for the Company’s Phase 2 clinical trial, which will test the efficacy on humans of Lucid-MS as a possible treatment for people to gain back mobility lost with multiple sclerosis. To date numerous animal models over the past decade showed Lucid-MS helped those animals regain their ability to walk.